Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 34121 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 37071 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 37308 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 37973 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 38594 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 39002 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 40245 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 42252 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 42356 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 42817 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 43006 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 44009 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 45233 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 46265 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 46381 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 46695 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 46866 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 47382 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 48713 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 48979 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 49469 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 49711 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 49824 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 53082 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 53323 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 53377 | Peak area normalized | male | Diabetic | no neuropathy |